Neuroimaging and Treatment Mechanisms in Major Depressive Disorder

Major Depressive Disorder (MDD) is a prevalent, disabling condition characterised by persistent low mood, anhedonia and cognitive disturbances. Neuroimaging modalities such as functional magnetic resonance imaging, diffusion tensor imaging and positron emission tomography have elucidated dysregulation within distributed brain networks, including the default mode, salience and frontoparietal attention circuits. These studies have revealed both structural alterations in grey and white matter and functional changes in intrinsic connectivity and task-evoked activation. Converging evidence suggests that early modulation of negative emotional bias and restoration of top–down cognitive control are key mechanisms underlying clinical improvement. Contemporary research aims to stratify patients into biologically informed subgroups, to predict individual treatment response to pharmacotherapy, psychotherapy and neuromodulation, and to refine targets for precision interventions in MDD.

Research from Nature Portfolio

Two recent investigations have advanced mechanistic understanding of MDD through multimodal neuroimaging and causal manipulation. One study derived personalised scores of intrinsic and task-evoked functional connectivity to parse six clinically distinct biotypes of depression and anxiety, each defined by unique patterns of default mode, salience and frontoparietal circuit dysfunction and corresponding differential response to pharmacological and behavioural interventions. A second investigation in non-human primates employed microstimulation of the subgenual cingulate cortex and concurrent local field potential recording to demonstrate that disruption of top–down influence from dorsolateral prefrontal regions induces a negative decision-making bias, illuminating a causal pathway between cortical regulation and limbic activity that may underlie depressive cognition.

Neuroimaging and Treatment Mechanisms in Major Depressive Disorder publication trend

The graph below shows the total number of articles in neuroimaging and treatment mechanisms in major depressive disorder across all publications each year (not limited to Nature Index journals).

Technical terms

Functional magnetic resonance imaging (fMRI): A non-invasive imaging technique that measures changes in blood oxygenation to infer neural activity.

Resting-state functional connectivity: The temporal correlation of spontaneous brain activity between regions during a lack of external task demands.

Default mode network (DMN): A set of interconnected brain regions active during passive rest and self-referential thought, typically deactivated during goal-directed tasks.

Salience network: A neural circuit, including anterior insula and cingulate cortex, responsible for detecting and filtering behaviourally relevant stimuli.

Microstimulation: The application of electrical stimulation to specific brain regions to causally modulate neural activity and assess its behavioural effects.

Biotypes: Distinct subgroups of patients characterised by reproducible neurobiological profiles, enabling stratification beyond symptom classification.

References

1. Personalized brain circuit scores identify clinically distinct biotypes in depression and anxiety. Nature Medicine (2024).
2. Cingulate microstimulation induces negative decision-making via reduced top-down influence on primate fronto-cingulo-striatal network. Nature Communications (2024).
3. Early changes in emotional processing as a marker of clinical response to SSRI treatment in depression. Translational Psychiatry (2016).
4. Neuroimaging Biomarkers for Predicting Treatment Response and Recurrence of Major Depressive Disorder. International Journal of Molecular Sciences (2020).
5. Magnetic resonance imaging for individual prediction of treatment response in major depressive disorder: a systematic review and meta-analysis. Translational Psychiatry (2021).
6. Prefrontal networks dynamically related to recovery from major depressive disorder: a longitudinal pharmacological fMRI study. Translational Psychiatry (2019).